Sanofi ends development of Clostridium difficile vaccine

IDMC concludes that the study is unlikely to meet its primary objective.

Following a planned interim analysis, the Independent Data Monitoring Committee (IDMC) for the Phase III Cdiffense clinical trial program concluded that the probability that the study will meet its primary objective is low.

Sanofi ends development of <i>Clostridium difficile</i> vaccine

Based on this, Sanofi has therefore decided to discontinue clinical development of its experimental Clostridium difficile vaccine, to focus on six key vaccine projects currently in development.

Cdiffense is a trial designed to test the efficacy and safety of a candidate toxoid vaccine in a subpopulation at risk of Clostridium difficile infection.

Sanofi Pasteur, the vaccines business of Sanofi responsible for the program, is informing all investigators, regulatory authorities and trial ethics committees. In addition, investigators are notifying study volunteers of the decision to stop the program. Data from all vaccinated volunteers in this trial will continue to be analysed for more information and shared with the scientific community.

Read More



Other news in “Research & Development”

Expanded GXP compliance increases Concept's breadth of services

Expanded GXP compliance increases Concept's breadth of services 

9 Feb 2018
'Effective' hair loss treatment candidate advances to Phase IIa

'Effective' hair loss treatment candidate advances to Phase IIa 

7 Feb 2018
Metrion Biosciences awarded £200k funding to further develop in-house drug discovery pipeline

Metrion Biosciences awarded £200k funding to further develop in-house drug discovery pipeline 

6 Feb 2018